AbbVie Goes Boldly Into Immuno-Neurology With Alector

 
• By Jessica Merrill

AbbVie agreed to pay $205m up front to biotech start-up Alector to research a portfolio of antibody targets to treat Alzheimer's and other neurodegenerative diseases by harnessing the immune system.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from Deals

More from Business